22-NHL-28-KP-PMC: A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma, ZUMA-22

Grants and Contracts Details

StatusActive
Effective start/end date3/6/23 → 12/5/25

Funding

  • Kite Pharma Incorporated: $25,943.00